852949-30-5
Chemical Structure
VK-0214
- CAS No.: 852949-30-5
- Formula:C23H25O5P
- Molecular Weight:412.42
InChIKey: GFJCILQBXUTOGN-UHFFFAOYSA-N
SMILES: O=P(O)(COC1=CC(C)=C(CC2=CC=C(C(CC3=CC=CC=C3)=C2)O)C(C)=C1)O
Biological Activity: VK-0214 is an orally effective agonist of the thyroid β receptor (TRβ). VK-0214 reduces the accumulation of very long-chain fatty acids (VLCFA) by activating ABCD2 expression. VK-0214 has the effect of regulating fatty acid metabolism. VK-0214 can serve as a GBM repurposing candidate compound identified through network pharmacology screening. VK-0214 can be used in research related to X-linked adrenoleukodystrophy (X-ALD) and glioblastoma[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
VK-0214 | 99.87% | VK-0214 is an orally effective agonist of the thyroid β receptor (TRβ). VK-0214 reduces the accumulation of very long-chain fatty acids (VLCFA) by activating ABCD2 expression. VK-0214 has the effect of regulating fatty acid metabolism. VK-0214 can serve as a GBM repurposing candidate compound identified through network pharmacology screening. VK-0214 can be used in research related to X-linked adrenoleukodystrophy (X-ALD) and glioblastoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. McGowan E, Sanjak J, Mathé EA, Zhu Q. Integrative Rare Disease Biomedical Profile based Network Supporting Drug Repurposing, a case study of Glioblastoma. Res Sq [Preprint]. 2023 Apr 18:rs.3.rs-2809689. doi: 10.21203/rs.3.rs-2809689/v1. Update in: Orphanet J Rare Dis. 2023 Sep 25;18(1):301. [Content Brief]
- [2]. McGowan DC, et al. SMALL-MOLECULE AGONISTS OF THYROID HORMONE RECEPTOR BETA (THR-β).
